Abbott launches Oncodetect test: Abbott Laboratories stock is 18.75 percent below its high

Abbott Laboratories (ISIN US0028241000) announced the commercial availability of its next-generation Oncodetect molecular residual disease test on October 26, 2026. The company is expanding its cancer diagnostics portfolio with a test designed to detect traces of tumor DNA during and after treatment, according to Abbott.

Oncodetect broadens variant tracking

The personalized, tumor-informed test combines whole-genome sequencing with MAESTRO technology. It tracks up to 5,000 patient-specific variants, compared with up to 200 variants in the first-generation test, and has a limit of detection below one part per million under high-end inputs, Abbott said in the October 26 release.

What does the new test add?

The commercial launch follows three dated milestones. On October 21, 2026, Abbott reported third-quarter sales of USD 13.013 billion, up 14.5 percent on a reported basis. On October 23, 2026, data presented at the European Society for Medical Oncology congress showed a 30 percent absolute improvement in sensitivity for colorectal cancer recurrence within two years. On October 26, 2026, Abbott announced the commercial availability of Oncodetect, according to the company release.

The operating context remains important for investors. Abbott said adjusted diluted earnings per share rose 9.2 percent to USD 1.42 in the third quarter, while GAAP diluted earnings per share was USD 0.53. The company tightened full-year 2026 adjusted earnings guidance to USD 5.50 to USD 5.55, as reported in its third-quarter earnings call summary.

Next dates for investors

Abbott's October 26 release says the test is available for patients with solid tumors and must be ordered by a healthcare provider. It also states that the test has not been cleared or approved by the U.S. Food and Drug Administration, a distinction that remains relevant as the company develops the commercial market.

Stock remains below its yearly high

Abbott Laboratories stock is 18.75 percent below its EUR 113.36 52-week high, based on the same euro quote context. The gap gives the new diagnostics launch a market backdrop, but the daily move remains below the threshold for a directional headline.

Abbott Laboratories stock was trading at EUR 92.10 at Lang & Schwarz on October 28, 2026 at 10:31 a.m. CET, 0.63 percent below the Xetra close of October 27, 2026 at EUR 92.68. The further course of trading is shown by the continuously updated real-time quote of Abbott Laboratories stock.

Market context: Market report S&P 500.

More news and analyses on Abbott Laboratories stock